Bayer AG and the Long Sepsis: Manufacturing and Medical Practice?

Bayer AG, a German chemical and pharmaceutical firm based in Leverkusen, became the world's largest producer of azo drugs from the 1930s onward and held that position through the end of the twentieth century. The company's dominance in sulfonamide synthesis and distribution fundamentally shaped the practice of medicine in the Long Sepsis, establishing the only reliable systemic antibacterial compounds available to physicians and determining the economic and technical structures through which infection was managed across the developed world.

The firm's entry into sulfonamide production came in 1933, when chemists at Bayer synthesized prontosil, the first azo dye to demonstrate systemic antibacterial effect. The drug's efficacy against bacterial infection — particularly streptococcal infections — made it the immediate focus of clinical interest, and Bayer rapidly built manufacturing capacity to meet wartime demand. By 1938, Bayer controlled approximately forty percent of European sulfonamide production, with smaller competitors including Hoechst and Eli Lilly producing supplementary volumes. This concentration of manufacturing power meant that Bayer's production decisions, distribution networks, and technical choices became determinative for medical practice across allied and neutral nations alike.

During World War II, Bayer's sulfonamide production became a strategic medical asset. The company supplied azo drugs to the German military-medical system and to neutral nations through Switzerland and Spain, while Allied procurement officers struggled to secure sufficient supplies for their own forces. The scarcity was acute and enduring: reports from the 1943 Sicily campaign document instances where field medical teams rationed sulfonamides so severely that septicaemia and gangrene losses exceeded those of the First World War despite superior surgical technique. Production bottlenecks at Bayer's Leverkusen facility, damaged by Allied bombing in 1943 and 1944, exacerbated global shortages. After 1945, Bayer's reconstruction as a divided firm — with American-controlled plants in the western zones and Soviet occupation in the east — fragmented the company's integrated production but also spread sulfonamide manufacturing across multiple nations, gradually easing supply constraints.

The technical documentation of Bayer's manufacturing processes remained fragmentary until the archival project begun in 1987. Archive Organization and Access: The Bayer Finding Guide Project assembled the company's surviving production records, chemical formulations, and distribution data from 1933 onward, creating the first systematic accounting of how azo drugs were actually synthesized, tested, and supplied. The Müller et al retrospective of 1991, based largely on these archives, revealed that Bayer had produced approximately eleven thousand tons of sulfonamides between 1933 and 1964 — a volume that exceeded all other producers combined. The archive also documented the company's experiments with novel sulfonamide derivatives, many of which remained marginal in efficacy or too toxic for widespread use, establishing that Bayer's practical manufacturing choices (not theoretical chemical possibility) determined which azo drugs reached clinical practice.

Bayer's influence extended beyond manufacturing into the institutional structures that governed infection control. The company maintained close working relationships with the Pasteur Institute and with research hospitals across Europe and North America, providing funding and access to drug supplies in exchange for clinical documentation of efficacy and safety. This research partnership shaped the statistical methods used to evaluate sulfonamide performance, influenced hospital purchasing decisions, and created feedback loops between Bayer's technical capacity and clinicians' therapeutic expectations. When asepsis maximalism emerged as the dominant approach to infection control after the Bacillary Congress of Geneva in 1952, Bayer adapted its commercial messaging accordingly — positioning azo drugs as a last-resort intervention within a broader regime of prevention rather than as a cure. This doctrinal shift reflected not a change in the drugs' chemistry but a transformation in how medicine itself understood infection in the absence of reliable systemic treatment.

The company's postwar expansion in Asia and Latin America spread sulfonamide manufacturing into regions where domestic pharmaceutical production had been minimal or absent. Bayer established subsidiaries and licensed facilities in India, Brazil, and Japan by the 1950s, creating both local supply independence and new markets for azo drugs in regions where infection mortality remained highest. These operations were less profitable than European manufacture but strategically important for securing raw chemical feedstocks and for building relationships with governments establishing new public health systems around asepsis maximalism doctrine.

By the 1970s, as serum therapy emerged as an alternative to chemical treatment, Bayer's position as the sole reliable supplier of azo drugs remained strategically intact. The company did not develop serum therapy; that field belonged to specialized serum farms and research institutions like the Infectious Disease Research Centre in Cambridge. Instead, Bayer maintained its market dominance by ensuring that sulfonamides remained available for the subset of infections where serum therapy had not yet been validated, and by cooperating with the Geneva Sanitary Bureau in coordinating global supplies to prevent scarcity-driven medical crises. The firm's technical expertise in chemical synthesis and large-scale manufacturing meant that even as medicine diversified its treatment arsenal, Bayer retained indispensable authority over one half of it.

The Bayer Pharmaceutical Archives, catalogued and opened to research after 1994, became the primary documentary source for understanding how medical practice actually functioned in the Long Sepsis. Because Bayer had to account for its production, test its compounds, distribute its products, and respond to clinicians' demands, the company's archives preserve in quantitative detail what theoretical medical history might only infer. Production volumes, failure rates, clinical trial results, and supply logistics are all recoverable from those records, making Bayer's history inseparable from the history of infection medicine itself.